<DOC>
	<DOC>NCT02062645</DOC>
	<brief_summary>The population that will be included in this study, will be regular Turkish hypertensive patients who are expected to consume sodium in high amounts. It is hypothesized that, in that population, amlodipine/valsartan will be effective at the same rate of blood pressure (BP) control rate as expected from literature.</brief_summary>
	<brief_title>Study of Efficacy and Safety of CVAA489 in Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine, Valsartan Drug Combination</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Male or female, above 18 years of age Diagnosis of essential hypertension Newly diagnosed, Previously untreated, or Currently untreated (not on regular antihypertensive treatment during the previous at least 1month period) Written informed consent Known or suspected secondary hypertension eGFR lower than 30 mL/min Use of any other hypertension treatments during the enrollment and need for using the related treatments during the study phase History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes. (i.e. valsartan, amlodipine, hydrochlorothiazide) History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases. Use of other investigational drugs within 5 halflives of enrollment, or within 30 days until the expected PD effect has returned to baseline, whichever is longer.Pregnant or nursing (lactating) women Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>essential hypertension</keyword>
</DOC>